| Rank |
Title |
Journal |
Year |
PubWeight™‹?› |
|
1
|
Pharmacokinetic, pharmacodynamic, and pharmacogenetic determinants of osteonecrosis in children with acute lymphoblastic leukemia.
|
Blood
|
2010
|
2.37
|
|
2
|
Asparaginase may influence dexamethasone pharmacokinetics in acute lymphoblastic leukemia.
|
J Clin Oncol
|
2008
|
2.29
|
|
3
|
Germline genetic variation in an organic anion transporter polypeptide associated with methotrexate pharmacokinetics and clinical effects.
|
J Clin Oncol
|
2009
|
2.20
|
|
4
|
Mrp4 confers resistance to topotecan and protects the brain from chemotherapy.
|
Mol Cell Biol
|
2004
|
1.93
|
|
5
|
Dexamethasone exposure and asparaginase antibodies affect relapse risk in acute lymphoblastic leukemia.
|
Blood
|
2011
|
1.88
|
|
6
|
Delayed methotrexate excretion in infants and young children with primary central nervous system tumors and postoperative fluid collections.
|
Cancer Chemother Pharmacol
|
2014
|
1.78
|
|
7
|
Shortening infusion time for high-dose methotrexate alters antileukemic effects: a randomized prospective clinical trial.
|
J Clin Oncol
|
2011
|
1.60
|
|
8
|
Population pharmacokinetic studies in pediatrics: issues in design and analysis.
|
AAPS J
|
2005
|
1.53
|
|
9
|
Folate pathway gene expression differs in subtypes of acute lymphoblastic leukemia and influences methotrexate pharmacodynamics.
|
J Clin Invest
|
2005
|
1.46
|
|
10
|
Gefitinib enhances the antitumor activity and oral bioavailability of irinotecan in mice.
|
Cancer Res
|
2004
|
1.41
|
|
11
|
Hypersensitivity reaction to high-dose methotrexate and successful rechallenge in a pediatric patient with osteosarcoma.
|
Pediatr Blood Cancer
|
2013
|
1.41
|
|
12
|
In vivo response to methotrexate forecasts outcome of acute lymphoblastic leukemia and has a distinct gene expression profile.
|
PLoS Med
|
2008
|
1.37
|
|
13
|
Plasma and cerebrospinal fluid pharmacokinetics of erlotinib and its active metabolite OSI-420.
|
Clin Cancer Res
|
2007
|
1.35
|
|
14
|
Activity of the multikinase inhibitor sorafenib in combination with cytarabine in acute myeloid leukemia.
|
J Natl Cancer Inst
|
2011
|
1.23
|
|
15
|
Gefitinib modulates the function of multiple ATP-binding cassette transporters in vivo.
|
Cancer Res
|
2006
|
1.23
|
|
16
|
UGT1A1 promoter genotype correlates with SN-38 pharmacokinetics, but not severe toxicity in patients receiving low-dose irinotecan.
|
J Clin Oncol
|
2007
|
1.20
|
|
17
|
Genome-wide study of methotrexate clearance replicates SLCO1B1.
|
Blood
|
2012
|
1.17
|
|
18
|
Methotrexate-induced neurotoxicity and leukoencephalopathy in childhood acute lymphoblastic leukemia.
|
J Clin Oncol
|
2014
|
1.10
|
|
19
|
Body mass index does not influence pharmacokinetics or outcome of treatment in children with acute lymphoblastic leukemia.
|
Blood
|
2006
|
1.10
|
|
20
|
Topotecan central nervous system penetration is altered by a tyrosine kinase inhibitor.
|
Cancer Res
|
2006
|
1.07
|
|
21
|
Phase I and clinical pharmacology study of bevacizumab, sorafenib, and low-dose cyclophosphamide in children and young adults with refractory/recurrent solid tumors.
|
Clin Cancer Res
|
2012
|
1.06
|
|
22
|
Genetic predictors of interindividual variability in hepatic CYP3A4 expression.
|
J Pharmacol Exp Ther
|
2009
|
1.05
|
|
23
|
The SWI/SNF chromatin-remodeling complex and glucocorticoid resistance in acute lymphoblastic leukemia.
|
J Natl Cancer Inst
|
2008
|
1.04
|
|
24
|
Expression of SMARCB1 modulates steroid sensitivity in human lymphoblastoid cells: identification of a promoter SNP that alters PARP1 binding and SMARCB1 expression.
|
Hum Mol Genet
|
2007
|
1.01
|
|
25
|
Compartment-specific roles of ATP-binding cassette transporters define differential topotecan distribution in brain parenchyma and cerebrospinal fluid.
|
Cancer Res
|
2009
|
0.99
|
|
26
|
Resumption of high-dose methotrexate after acute kidney injury and glucarpidase use in pediatric oncology patients.
|
Cancer
|
2012
|
0.99
|
|
27
|
Whole-body physiologically based pharmacokinetic model for nutlin-3a in mice after intravenous and oral administration.
|
Drug Metab Dispos
|
2010
|
0.94
|
|
28
|
Tyrosine kinase inhibitor enhances the bioavailability of oral irinotecan in pediatric patients with refractory solid tumors.
|
J Clin Oncol
|
2009
|
0.94
|
|
29
|
Cefixime allows greater dose escalation of oral irinotecan: a phase I study in pediatric patients with refractory solid tumors.
|
J Clin Oncol
|
2006
|
0.94
|
|
30
|
Gene expression and thioguanine nucleotide disposition in acute lymphoblastic leukemia after in vivo mercaptopurine treatment.
|
Blood
|
2005
|
0.93
|
|
31
|
Phase I study of the tolerability and pharmacokinetics of palifermin in children undergoing allogeneic hematopoietic stem cell transplantation.
|
Biol Blood Marrow Transplant
|
2012
|
0.93
|
|
32
|
Population pharmacokinetic analysis of topotecan in pediatric cancer patients.
|
Clin Cancer Res
|
2007
|
0.93
|
|
33
|
Application of a highly specific and sensitive fluorescent HPLC method for topotecan lactone in whole blood.
|
Biomed Chromatogr
|
2009
|
0.91
|
|
34
|
Interferon-gamma pharmacokinetics and pharmacodynamics in patients with colorectal cancer.
|
Cancer Chemother Pharmacol
|
2003
|
0.89
|
|
35
|
Voriconazole plasma concentrations in immunocompromised pediatric patients vary by CYP2C19 diplotypes.
|
Pharmacogenomics
|
2014
|
0.89
|
|
36
|
Msh2 deficiency attenuates but does not abolish thiopurine hematopoietic toxicity in msh2-/- mice.
|
Mol Pharmacol
|
2003
|
0.88
|
|
37
|
Phase I trial, pharmacokinetics, and pharmacodynamics of vandetanib and dasatinib in children with newly diagnosed diffuse intrinsic pontine glioma.
|
Clin Cancer Res
|
2013
|
0.88
|
|
38
|
Mechanisms of dexamethasone-induced disturbed sleep and fatigue in paediatric patients receiving treatment for ALL.
|
Eur J Cancer
|
2010
|
0.87
|
|
39
|
Development and validation of limited sampling models for topotecan lactone pharmacokinetic studies in children.
|
Cancer Chemother Pharmacol
|
2005
|
0.87
|
|
40
|
Population PK/PD model of homocysteine concentrations after high-dose methotrexate treatment in patients with acute lymphoblastic leukemia.
|
PLoS One
|
2012
|
0.84
|
|
41
|
Using plasma topotecan pharmacokinetics to estimate topotecan exposure in cerebrospinal fluid of children with medulloblastoma.
|
Neuro Oncol
|
2006
|
0.84
|
|
42
|
Clinical pharmacokinetics of amifostine and WR1065 in pediatric patients with medulloblastoma.
|
Clin Cancer Res
|
2010
|
0.82
|
|
43
|
Between-course targeting of methotrexate exposure using pharmacokinetically guided dosage adjustments.
|
Cancer Chemother Pharmacol
|
2013
|
0.82
|
|
44
|
Pharmacokinetics and pharmacodynamics of oral etoposide in children with relapsed or refractory acute lymphoblastic leukemia.
|
J Clin Oncol
|
2003
|
0.82
|
|
45
|
Total and active rabbit antithymocyte globulin (rATG;Thymoglobulin) pharmacokinetics in pediatric patients undergoing unrelated donor bone marrow transplantation.
|
Biol Blood Marrow Transplant
|
2009
|
0.81
|
|
46
|
Formalizing an integrative, multidisciplinary cancer therapy discovery workflow.
|
Cancer Res
|
2013
|
0.81
|
|
47
|
Development of a pharmacokinetic limited sampling model for temozolomide and its active metabolite MTIC.
|
Cancer Chemother Pharmacol
|
2005
|
0.79
|
|
48
|
P-glycoprotein, but not multidrug resistance protein 4, plays a role in the systemic clearance of irinotecan and SN-38 in mice.
|
Drug Metab Lett
|
2010
|
0.78
|
|
49
|
Prophylactic Trimethoprim-Sulfamethoxazole Does Not Affect Pharmacokinetics or Pharmacodynamics of Methotrexate.
|
J Pediatr Hematol Oncol
|
2016
|
0.76
|
|
50
|
Genetics of pleiotropic effects of dexamethasone.
|
Pharmacogenet Genomics
|
2017
|
0.75
|